Recent advances in biology have revealed the complexity of diseases such as cancer and autoimmune disorders, demonstrating that these diseases are typically driven by many different factors. Physicians must frequently use combinations of drugs to effectively address complex disease biology. Monoclonal antibody (mAb) therapeutics have been used for years to treat many diseases, but because they modulate only a single disease target, they alone are often insufficient to be fully efficacious. To treat disease more effectively and to overcome the regulatory and economic hurdles that face combinations of biological therapeutics, future biotherapeutic drugs must transition to more sophisticated multi-specific and multi-valent therapeutics that can concomitantly and synergistically disrupt diseases through multiple points of susceptibility.
Zyngenia's technology was specifically developed to create a new class of drugs that is ideally suited to treating multi-factorial diseases. With this technology, Zyngenia is developing single-molecule biotherapeutics that possess the drug-like properties of mAbs, but that also have the ability to simultaneously and synergistically engage up to five targets. Because of this ability to add different specificities and to tune valency in a single molecule, these novel biotherapeutics can contain several agonists and/or antagonists of different disease targets.
Zyngenia's drug candidates retain the desired properties of mAbs, while offering enhanced specificity to disease tissue and ability to interact with multiple biologic pathways of interest. This strategy has the potential to boost therapeutic efficacy and reduce toxicity. As such, Zyngenia's multi-specific, multi-valent therapeutics hold significant potential to better address the complexity of disease.